Posted on

The Window of Opportunity is Here

Published at smallcapexclusive.com

 

Mydecine Innovations Group Inc. (CSE:MYCO) (OTC:MYCOF) (FRA:0NFA) Continues to Advance Research & Development Initiatives in the Field of Natural Medicines

 

Prior  to his monumental comeback at the age of 54, former World Heavyweight Boxing Champion Mike Tyson was delivered a message from a frog.

More precisely, he received the message from a psychedelic sourced from the venomous Colorado River Toad, also known as the Sonoran Desert Toad, known as 5-MeO-DMT (aka “5-MeO” or “frog venom”).

“I took the [5-MeO-DMT] and the medicine told me to get into shape,” Tyson said to USA Today.[1] “It really blew my mind. It told me to come back and start getting in shape.”

With the help of the psychedelic, Tyson lost more than 100 pounds for a major exhibition bout against Roy Jones Jr.—his first fight in 15 years.

Said to be more transcendent and less visual than its plant-based cousin DMT, 5-MeO-DMT can be a stronger experience for some.

Most 5-MeO trips are kept to under an hour, and require far smaller dose sizes than other psychedelics.

But even more impressive is the fast-acting psychedelic’s potential, which researchers at Johns Hopkins have discovered can bring about improvements in depression and anxiety.[2]

The potential for psychedelics to treat mental health issues is truly on the precipice of a major breakout—especially as acceptance of this once taboo form of treatment begins to make its way into mainstream medicine conversations.

Tyson is not alone, being among elite athletes who have looked to psychedelics to turn their life around.

Former Los Angeles Lakers star Lamar Odom successfully used the psychedelic drugs ketamine and ibogaine to combat his drug addiction[3]—crediting the drugs with saving his life.

There are other success stories, including those of NHL Enforcers Riley Cote[4] and Daniel Carcillo,[5] former NFL player Kerry Rhodes,[6] and former UFC MMA Fighters Ian McCall[7] and Dean Lister,[8] utilizing previously taboo treatments such as ayahuasca, ketamine, ibogaine, psilocybin, MDMA, and now 5-MeO-DMT.

Now these treatments are shifting from anecdotal to potential alternative medicinal reality, with the advent of clinical trials being advanced by some of the world’s top psychedelic and mental health professionals, including doctors, scientists, and molecular researchers.

Some analysts are projecting the psychedelics medicine industry to reach $6.85 billion by 2027.[9] As psychedelic companies gain acceptance within the investment community, there is an opportunity to review these companies in a new light.

Recently, a new psychedelics ETF began trading in January, and others are emerging to meet the demand, with two surpassing the US$1 billion market cap threshold.

Highlighted within this group of psychedelic companies is one company underpinned by thought leaders in medicine and science, warranting further due diligence and review: Mydecine Innovations Group Inc. (CSE:MYCO) (OTC:MYCOF) (FSE: 0NFA).

The company recently announced and closed a bought deal financing of C$17.25 million, announced uplisting to the NASDAQ, and was just included in the inaugural psychedelics-inspired ETF.

With several clinical trials announced in 2020 and early 2021, including involvement with the first lab-based study co-sponsored by the National Institute for Health Research at Imperial College of London, and a Phase 2A clinical study on PTSD in veterans, EMS, and front-line workers, Mydecine continues to approach research and development with cautious optimism as their programs develop.

7 Reasons Why We’re Watching Mydecine Innovations Group Inc. (CSE:MYCO) (OTC:MYCOF) (FSE: 0NFA)

  1. World-Renowned Medical and Scientific Advisory is building out a robust R&D pipeline of nature-sourced psychedelic-assisted therapeutics, novel compounds, therapy protocols, and unique delivery systems.
  2. Exclusive Access to a Full cGMP Certified Pharmaceutical Manufacturing Facility with the ability to import/export, cultivate, extract/isolate, and analyze active mushroom compounds with full government approval through Health Canada.
  3. Operates Out of a State-of-the-Art Mycology Lab in Denver, CO to focus on genetic research for scaling commercial cultivation of rare (non-psychedelic) medicinal mushrooms
  4. Seven Patent Pending Applications That Represent Thousands of Inventions with multiple layers of protection on the company’s proprietary medical development pipeline.
  5. Proprietary Digital Health Platform, Mindleap, allows Mydecine to generate revenue in the fast-growing US$41.4 billion telemedicine market
  6. Numerous Clinical Trials are currently underway, including a Phase 2A clinical trial on PTSD in Veterans, EMS, and Front Line Workers, a First-of-its-Kind Microdose Study, and Preclinical Animal Work for a Late-State Addiction Study aiming at a Mechanistic Understanding of Psilocybin.
  7. Numerous Novel Next Generation Drugs Under Development: Mydecine is currently developing numerous novel next generation drugs for the treatment of various indications to improve upon the first generation of psychedelic medicines

 

Combatting the Mental Health Crisis with Psychedelics

COVID-19 is taking its toll on all of us, including rising deaths of despair[10] and an urgent mental health crisis among health workers.[11]

A recent study that screened 402 survivors of COVID-19 found that 55% presented a clinical score for at least one mental disorder, including anxiety (42%), insomnia (40%), depression (31%), PTSD (28%), and OCD (20%).[12]

Anxiety disorders are the most common mental illness in the US, affecting 40 million adults—or 18.1% of the population every year.[13]

Sadly, only 36.9% of those suffering receive treatment, and MORE THAN HALF of people who take antidepressants never get relief.[14]

In cases of Veterans with PTSD, several patients are put on SSRIs, however, only 20-30% of patients achieve complete remission.[15]

SOMETHING needs to change.

Thankfully, we’re witnessing what’s being deemed a “Paradigm Shift in Psychiatric Research and Development.”[16]

That paradigm shift is coming from PSYCHEDELICS.

Now, we’re seeing mainstream coverage being given to the novel mental health approach on 60 Minutes,[17] Forbes,[18] Fox Business,[19] NPR,[20] and Today.[21]

A new wave of mental health sufferers are turning towards small doses of psychedelics, known as “micro-dosing”, to cope with depression and anxiety,[22] or even to achieve higher levels of concentration and creativity,[23] as experts are saying that “legalization is inevitable” for treatments involving psilocybin and other psychedelic treatments.

Mydecine Innovations Group Inc. (CSE:MYCO) (OTC:MYCOF) (FSE: 0NFA) is establishing psychedelic-based therapies, and addressing the unmet needs of high-risk constituents.[24]

The concept is to assist those who have been failed by the current regime of SSRIs and other established antidepressants.

Mydecine’s (CSE:MYCO) (OTC:MYCOF) (FSE: 0NFA) ongoing research to date includes clinicals using psilocybin therapy for PTSD[25] (which has been featured in FORBES[26]), a clinical trial initiative with leading European Research Institute Leiden University Medical Center of the Netherlands,[27] and the first lab-based study of established microdosers at Macquarie University in Australia.[28]

An Evolving Industry Gaining Traction

While therapists are looking at innovative therapies to treat patients, the investment communities within Wall Street and Silicon Valley are also investigating new ways to approach the psychedelic sector. [29]

Naysayers of whether this type of “new medicine” could ever get mainstream acceptance were silenced, when Compass Pathways (backed by ATAI Life Sciences AG), received FDA breakthrough therapy designation on a psilocybin treatment, perhaps better known as the active medical ingredient in magic mushrooms.[30]

ATAI has raised more than US$100 million from major investors such as PayPal co-founder Peter Thiel—and later this year, they are expected to go public at a valuation of US$1-2 billion.[31]

Mydecine continues to expand its technical platforms and outreach with its available and downloadable app: MindLeap.

Through its proprietary Mindleap platform, Mydecine is also giving practitioners the ability to aid their patients better through telehealth abilities and an AI-powered progress monitoring program.

Mindleap is an after-care smart app platform that not only connects patients with their therapists, but also can significantly improve upon monitoring progress, provide follow-up treatment, and give patients other beneficial activities such as meditation, breathing work, and yoga instruction.

Mindleap currently has over 60 specialists with thousands of downloads to date, and is available on both iOS and Android devices.

Comparing Mental Health Psychedelic Stocks

At the end of 2020, the first-ever Psychedelics ETF was announced, which includes 17 companies in the US and Canada, and began trading on January 26, 2021, under the ticker PSYK on the NEO exchange. Announced among and included in that group of 17 was Mydecine Innovations Group Inc. (CSE:MYCO) (OTC:MYCOF) (FSE: 0NFA).

Let’s take a look at some of the other Big Pharma/Mental Health Medicine Stocks.

*Market cap and share price taken from Yahoo Finance on March 9, 2021

 

As you can see, Mydecine (CSE:MYCO) (OTC:MYCOF) (FSE: 0NFA) is already far along in the licensing process when compared to its peers.

 

Economic Advantages from Mushroom Research

Out of all of Mydecine’s advantages in the field of developing new medicines, perhaps its largest is its relationship with the University of Alberta, which holds an 11-year-old aged Schedule I license to research, develop, and produce a number of unique APIs (Active Pharmaceutical Ingredients) from their naturally-sourced cGMP psychedelic extracts.

Through this partnership, Mydecine (CSE:MYCO) (OTC:MYCOF) (FSE: 0NFA) has established the World’s First Natural-Sourced cGMP Psilocybin supply for Global Research, Sales, and Distribution.[35]

Currently, scientists are paying $7,000 to $10,000 per gram[36] for synthetic mushroom ingredients—whereas MYCO can legally derive and produce the real organic version of the same ingredients for significantly lower than what is currently available.

‍

Mydecine’s Upcoming Timeline

Mydecine’s Thought Leadership

Mydecine (CSE:MYCO) (OTC:MYCOF) (FSE: 0NFA) has assembled a talented team of thought leaders, whose accomplishments include:

  • 100+ published peer-reviewed studies/papers
  • World-class team coming from Pfizer, Novartis, Yale, Imperial College, and Canadian, US, and EU Militaries
  • Proven medical development and approval experience
  • 30+ years of combined psychedelic industry experience
  • Accomplished entrepreneurs, multiple successful exits
  • 7-Nobel Peace Prize Nominee

Joshua Bartch, Director, CEO & Co-Founder Bartch’s entrepreneurial career took off in 2009 when he co-founded AudioTranscriptionist.com and founded the Denver-based dispensary, Doctors Orders. Following these ventures, Mr. Bartch founded a boutique investment firm that operated throughout the US and Canadian markets. In 2014, Bartch co-founded Cannabase.io, the USA’s most significant legal and sophisticated pot wholesale platform. In 2015, Cannabase.io was acquired by Helix TCS.

Damon Michaels, Director, COO & Co-Founder Prior to joining MIG, Michaels was consulting for various hemp businesses through his company, Emerald Baron. Before that, he served as GM for the leading multi-platform cannabinoid research and technology firm based in Colorado called ebbu, which was acquired by Canopy Growth for CA$429 million in November 2018. Michaels developed a national snowboard brand with his team, was one of four entrepreneurs who created Colorado’s first-ever glass recycling company, and was on the business development team for a Google Ventures Company.

Robert Roscow, MA – CSO & Co-Founder With expertise in genomics, evolution, and molecular biology, Roscow has previously worked at both Canopy Growth and ebbu, where he ran the genetics divisions. He has filed multiple patents and holds numerous publications under his belt, including Nature and Rolling Stone.

Professor Eric Vermetten MD, Ph.D. Colonel, an internationally recognized leader in the treatment of PTSD and other mental disorders and an active Colonel of the Dutch military. He is also professor of Medical-Biological and Psychiatric Aspects of Psychotrauma, LUMC/University of Leiden. The chair was established by Arq Psychotrauma Research and the Dutch Ministry of Defense. Eric Vermetten is an active clinical psychiatrist at the MGGZ in Utrecht (Military Mental Health care). From 1991 he has been linked to several universities as a researcher, including Stanford University, Yale University, and Emory University.

Dr. Vermetten has published over 300 articles and book chapters on topics ranging from large longitudinal studies following soldiers’ deployments to innovative approaches to treatment. He continues to be a leader within the international psych traumatology community within NATO and beyond.

Dr. Rakesh Jetly, OMM, CD, MD, FRCPC is currently the Head of the Centre of Excellence on Mental Health in Ottawa, Ontario, and an associate professor of psychiatry at Dalhousie University, and the University of Ottawa. He has published numerous articles in professional journals and presents nationally and internationally on such topics as post-traumatic stress disorder and operational psychiatry.

Carl Castro is the research director for the USC Center for Innovation and Research on Veterans and Military Families. Castro has authored more than 150 scientific articles and reports in numerous areas and currently serves as chair of a NATO research group on military mental health training. He serves as an advisor for several Department of Defense research panels focused on psychological health.

7 Investment Highlights of Mydecine Innovations Group Inc. (CSE:MYCO) (OTCQB:MYCOF) (FRA: 0NFA)

  1. Management, research teams, partners (military, scientists, researchers) and one of the original senior marketing executives that launched Red Bull in the US
  2. Substances Dealer’s Licenses from Health Canada that allow Mydecine (CSE:MYCO) (OTC:MYCOF) (FSE: 0NFA) the ability to cultivate, import, export, extract, and commercialize psilocybin and other functional mushroom products.
  3. Technology and Analytics from the Mindleap platform that’s connected to clinics across the globe, providing TONS of data that’s privacy protected, and can improve upon the AI capabilities of this state-of-the-art telemedicine service.
  4. Equipped for industry leading research through 7,500 sq ft Colorado Lab
  5. Access to Top 15 Global Research through the University of Alberta.
  6. Low-cost cultivation that’s capable of deriving APIs from mushrooms at a cost of pennies per gram when scientists are currently paying $7,000-$10,000 per gram for synthetically derived ingredients, giving HUGE leverage to complete clinical studies.

First-of-its-Kind clinical trials (featured in Forbes), with a current pipeline of 8 studies lined up through 2021, through 7 different respected research institutions.

[1] https://www.usatoday.com/story/sports/boxing/2020/11/27/mike-tyson-roy-jones-jr-fight-psychedelic-drugs/6442985002/

[2] https://www.hopkinsmedicine.org/news/newsroom/news-releases/fast-acting-psychedelic-associated-with-improvements-in-depressionanxiety

[3] https://psychedelicspotlight.com/how-psychedelics-saved-former-nba-star-lamar-odom-from-drug-addiction/

[4] https://psychedelicspotlight.com/how-psychedelics-helped-riley-cote/

[5] https://www.forbes.com/sites/amandasiebert/2020/11/26/these-four-former-pro-athletes-are-using-psychedelics-to-heal-their-brain-injuries/?sh=33302f5c70d7

[6] https://www.forbes.com/sites/amandasiebert/2020/11/26/these-four-former-pro-athletes-are-using-psychedelics-to-heal-their-brain-injuries/?sh=33302f5c70d7

[7] https://www.msn.com/en-us/sports/mma-ufc/ufc-eyes-psychedelics-as-therapy-for-fighters-brain-injuries/ar-BB1cLl7N

[8] https://www.forbes.com/sites/amandasiebert/2020/11/26/these-four-former-pro-athletes-are-using-psychedelics-to-heal-their-brain-injuries/?sh=33302f5c70d7

[9] https://www.prnewswire.com/news-releases/psychedelic-drugs-market-projected-to-reach-6-85-billion-by-2027–301082594.html

[10] https://www.sciencenews.org/article/deaths-of-despair-depression-mental-health-covid-19-pandemic

[11] https://abcnews.go.com/US/urgent-mental-health-crisis-health-workers-facing-immense/story?id=75925696

[12] https://www.ctvnews.ca/health/coronavirus/mental-disorders-affect-more-than-half-of-covid-19-survivors-study-1.5050969

[13] https://adaa.org/understanding-anxiety/facts-statistics

[14] https://www.sciencedaily.com/releases/2009/10/091023163346.htm

[15] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5047000/

[16] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6041963/

[17] https://www.cbsnews.com/news/psilocybin-active-agent-in-magic-mushrooms-could-treat-addiction-depression-and-anxiety-60-minutes-2019-10-10/

[18] https://www.forbes.com/sites/robinseatonjefferson/2019/09/12/magic-mushrooms-as-medicine-johns-hopkins-scientists-launch-center-for-psychedelic-research-say-psychedelics-could-treat-alzheimers-depression-and-addiction/#3ec549efc171

[19] https://video.foxbusiness.com/v/6085830149001/#sp=show-clips

[20] https://www.npr.org/2019/10/01/766057380/how-magic-mushrooms-can-help-smokers-kick-the-habit?fbclid=IwAR0HsI05xIPrh8cl3CiJj1SD-lVKZ8wXXEDQfs2TEwfqKit9hUyYSPfeOfM&utm_campaign=storyshare&utm_medium=social&utm_source=facebook.com

[21] https://www.today.com/video/could-psychedelic-drugs-be-a-cure-for-depression-71467589539

[22] https://globalnews.ca/news/7610610/pandemic-mushrooms-anxiety-micro-dosing/

[23] https://futurism.com/neoscope/nose-spray-microdosing-psilocybin

[24] https://www.prnewswire.com/news-releases/psychedelic-compounds-could-be-used-in-mental-healthcare-301093625.html

[25] https://www.globenewswire.com/news-release/2020/08/13/2077822/0/en/Mydecine-Innovations-Group-Featured-in-Forbes-for-the-First-Of-Its-Kind-Clinicals-Using-Psilocybin-Therapy-For-PTSD.html

[26] https://www.forbes.com/sites/javierhasse/2020/08/12/psilocybin-trial-ptsd-veterans/#33e5b34b4601

[27] https://www.newswire.ca/news-releases/mydecine-innovations-group-inc-announces-neuropharm-inc-commences-ptsd-clinical-trial-initiative-with-leading-european-research-institute-852788451.html

[28] https://www.mydecine.com/news/mydecine-innovations-group-sponsors-first-lab-based-study-of-established-microdosers-at-macquarie-university-in-australia

[29] https://www.wsj.com/articles/silicon-valley-and-wall-street-elites-pour-money-into-psychedelic-research-11597941470

[30] https://compasspathways.com/compass-pathways-receives-fda-breakthrough-therapy-designation-for-psilocybin-therapy-for-treatment-resistant-depression/

[31] https://www.cnbc.com/2020/11/23/peter-thiel-backs-psychedelics-startup-atai.html

[32]https://www.globenewswire.com/news-release/2020/08/18/2079824/0/en/Mydecine-Launches-World-s-First-Natural-Sourced-cGMP-Psilocybin-for-Global-Research-Sales-and-Distribution-Enterprise.html

[33]https://mindmed.co/news/press-release/mindmed-announces-successful-completion-of-pre-ind-meeting-with-the-fda-for-project-lucy

[34]https://compasspathways.com/compass-pathways-receives-fda-breakthrough-therapy-designation-for-psilocybin-therapy-for-treatment-resistant-depression/

[35] https://finance.yahoo.com/news/mydecine-launches-worlds-first-natural-113000629.html

[36] https://qz.com/1235963/scientists-who-want-to-study-psychedelic-mushrooms-have-to-pay-7000-per-gram/

Posted on

BETTER PLANT’S JUSU HOME EXPANDS LINE OF ECO-FRIENDLY HOUSEHOLD CLEANING PRODUCTS

Vancouver, B.C. –  March 17, 2021: Better Plant Sciences Inc.(CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant” or the “Company”) is pleased to announce the launch of Jusu Home, a new eco-friendly line of household products, including a Rosewood Sweet Orange Laundry Detergent and a Sweet Orange Lime Stainless Steel Cleaner.

To round out the Jusu Home line, new Home Care Bundles are now available on Jusu’s  recently revamped website, Getjusu.com. Better Plant currently has 67 different  plant-based  Jusu Home and Body products for sale and plans to regularly launch new products from its extensive catalogue of proprietary formulas,  based on market and consumer data.

A campaign to promote Jusu Home products is underway to run  ad placements on Oprah’s SuperSoul Conversations, SHE with Jordan Lee Dooley, and Nutrition Diva podcasts. Jusu Home products are available in Canada at getjusu.com and from trusted retailers such as Nature’s Way Holistic Health Center, Purple Carrot Health Foods and Wellness Inc., and The Cleaning Co-operative.

“The demand for hygiene and cleanliness products suitable for both residential and commercial spaces has been rising, and is expected to continue to rise,”  said Joelle Fiorito, Director  of Operations for Better Plant. “Jusu Home products are high-quality, eco-friendly, non-toxic, naturally fragrant, and contain no harmful chemicals. They function as a suitable eco-friendly alternative to harsh chemical cleaners and bleaches, which can cause irritation.

Better Plant has increased research and development in this area and is focused on launching high-quality  eco-friendly goods.

“We have a loyal customer base that has guided us along the way with genuine feedback and love for our home cleaning products,”  said Joelle Fiorito. “Our long-time wholesale customers call us often just to say they don’t know what they would do without our products and that their customers feel the same. It’s an exciting time for Jusu not only because we have our long-term, loyal customers, but also because we are gaining new customers that have just as much love for our products.”

With this new product launch, Getjusu.com is also getting a fresh new look with improved usability and eye-catching features. Notable features of the new eCommerce site include updated images and video content, improved U/X, and subscription services for customers to build their own bundles to reorder.

According to a report by Prophecy Market Insights, The global green cleaning products market accounted for US$ 3.9 billion in 2019 and is estimated to be US$ 11.6 billion by 2029 and is anticipated to register a CAGR of 11.8%.

 

About Jusu

Jusu Wellness Inc. is a wholly owned subsidiary of Better Plant and it owns and operates Jusu,  a full spectrum wellness brand with a mission to enlighten consumers to the protective and effective properties of plant based products. Jusu is committed to making pure, organic, plant-based products for consumption, body and personal care. This includes one JUSU Bar location and brick-and-mortar juice bar franchise opportunities as well as an extensive direct-to-consumer product offering including cold-pressed juices, skin care and body products, aromatherapy and home cleaning lines. Jusu is fully dedicated to offering consumers healthier alternatives to currently available chemical-based skin care, edible, and beverage products.

To purchase Jusu Wellness products visit getjusu.com,  or follow @jusu on Instagram.

 

About Better Plant

Better Plant offers plant-based products for optimum health and wellness. It is a vertically integrated company with a team whose complementary experience enables acquisition, development, manufacturing, and direct-to-consumer distribution of its products. Its all-natural products vary from juice cleanses to home products to personal care products, all without chemicals or harmful ingredients. It has an extensive catalogue of over 400 proprietary plant-based product formulas. Better Plant currently has over 70 plant-based products for sale through eCommerce and/or in retail stores under the brands Jusu, Urban Juve, and Wright & Well. Better Plant also offers operational and support services to companies in which it has an equity interest. Better Plant also owns approximately 27.7% of NeonMind Biosciences Inc. (CSE:NEON).

For more information on Better Plant, visit betterplantsciences.com or follow @betterplantsciences on Instagram.

Penny White, President & CEO

penny@betterplantsciences.com

1-833-515-2677

 

Investor Relations:

Alexandra Dumanski

invest@betterplantsciences.com

1-833-515-2677

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

 

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation.  Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements.  Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of COVID-19, the potential for not acquiring any rights as a result of the patent  application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen.  Demand for the company’s products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets.  Better Plant cautions readers not to place undue reliance on forward-looking statements provided by Better Plant, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better Plant expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

Posted on

New Wave Subsidiary, N2 Logics Enters Partnership Agreement with Toronto-Based Naturopathic Doctor, Dr. Elizabeth Goldspink, to Collaborate on Multiple Developments

TORONTO, March 11, 2021 /CNW/ – NEW WAVE HOLDINGS CORP. (the “Company” or “New Wave”) (CSE: SPOR) (FWB: 0XM2) (OTCPK: TRMNF) an investment issuer that provides capital and support services, announces that N2 Logics Inc. (“N2”), an entity in which New Wave owns a significant interest, has signed an agreement to work alongside Dr. Elizabeth Goldspink on multiple upcoming ventures.

New Wave Holdings Logo (CNW Group/New Wave Holdings Corp.)
New Wave Holdings Logo (CNW Group/New Wave Holdings Corp.)

Following the partnership agreement commencing on March 22nd, 2021, N2 Logics and Dr. Goldspink are set to collaborate on several developments in the upcoming months. The e-commerce and digital marketing company plans to roll out its own line of functional mushroom products in the UK before this summer, which are currently being developed by Dr. Goldspink. N2 Logics is anticipating positive sales growth with the addition of this mushroom collection to its existing products, with a 18% increase in projected revenue following its launch.

As part of the partnership, N2 Logics will be using their Bloom Botanics brand to leverage sales of Dr. Goldspink’s Papillex & AHCC® by Papillex supplements via its ecommerce site and Amazon. The recently announced Northern Ireland grace period extension will allow N2 Logics to streamline product distribution throughout the UK and across Europe from one location.

Dr. Goldspink is a Toronto-based Naturopathic Doctor and a prominent Health & Wellness Entrepreneur who is frequently featured as a wellness expert on CityTV’s “CityLine”. Dr. Goldspink studied mind body medicine at Harvard Medical School, under Dr. Herbert Benson, MD, who is the world leader in the study, advancement, and clinical practice of mind/body medicine. She writes for various print and online publications, including Integrative Healthcare Practitioners (IHP), and formulates natural health products (NHP’s) for various innovative companies.

“We’re thrilled to be working with an accomplished and distinguished naturopathic doctor such as Dr. Elizabeth Goldspink,” commented Willie Tsang, CEO of New Wave. “She has a wealth of knowledge and experience in the natural health care and wellness sphere, and her expertise will contribute significantly to the growth and development of our company as we continue to evolve. We look forward to working closely with her on a number of upcoming projects, which we’re confident will result in successful outcomes that will be mutually beneficial.”

“Mushrooms are the future of wellness and I am excited to help make pure, transparent, and therapeutic blends accessible to the people who will benefit from them. I am looking forward to collaborating with New Wave on multiple ventures,” said Dr. Elizabeth Goldspink.

ABOUT NEW WAVE HOLDINGS CORP.

New Wave Holdings Corp. (CSE: SPOR, FWB: 0XM2, OTCPK: TRMNF) is an investment issuer focused on the burgeoning nutraceutical and psychedelic sector and support for adaptive and progressive health and wellness products and therapies. New Wave subsidiaries contain various health and beauty products within its portfolio of non-psychoactive plants and fungi as it continues to expand its product distribution through vertical integration to provide end to end solutions while capturing a high margin business model.

Investors interested in connecting with New Wave Holdings can learn more about the company and contact the team at http://newwavecorp.com.

ABOUT Papillex™
Papillex™ is a company that offers a clinically-researched, nutrient-rich supplement that is designed to support the immune system in response to HPV. Papillex™ optimizes natural immunity and replaces key nutrients that have been found to be missing and low in people with persistent HPV symptoms. Additionally, Papillex™ also offers a medicinal mushroom product from the mycelium of shiitake mushrooms called AHCC®, which is backed by over 20 human clinical studies. AHCC® has been demonstrated to help the human body better respond to HPV and other viral infections.

You can find out more at https://papillex.com

ABOUT N2 LOGICS INC.
The N2 team brings over 10 years of experience in the field of online E-commerce and digital marketing, they utilize established and true methodologies to attract high quality traffic online through lead generation and conversion optimization. Based on the current digital marketing needs, they focus on world class tactics and digital optimization to provide return on investments. Uniquely positioned with New Wave, N2 will have the ability to grow globally while developing and discovery various products within the industry.

Investors interested in connecting with N2 can learn more about the company and contact the team at http://www.n2logics.com

ABOUT BLOOM BOTANICS E-COMMERCE PLATFORM
Bloom Botanics a highly innovative E-commerce platform that was formed when a collective of E-commerce experts from the UK, Ireland and the North American Cannabis and Cannabis Accessory industry realised there was a significant opportunity to create Bloom Botanics to carry an impressive range of various of CBD and mushroom based products and continue to aggressively increase its presence in this space from a product and geographical basis. The Bloom Botanics team currently consists of industry experts from 6 different European countries and will be looking to expand that team and its expertise moving forward.

Investors interested in connecting with Bloom Botanics can learn more about the company and contact the team at https://bloombotanics.co.uk

Information relating to Bloom Botanics, contained in this news release was provided by Bloom Botanics and/or its agent and has not been independently verified by the Company. The Company does not take responsibility for the accuracy of such information.

The CSE has not in any way passed on the merits of the Acquisition, and neither has approved nor disapproved the contents of this press release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

FORWARD-LOOKING INFORMATION DISCLAIMER

Certain statements contained in this news release may constitute forward–looking information, including but not limited to, applicable regulatory approval in connection with the Acquisition, the closing of the Acquisition, expansion of operations, size and quality of future tournaments and projections regarding attendance at future events. Forward–looking information is often, but not always, identified by the use of words such as “anticipate”, “plan”, “estimate”, “expect”, “may”, “will”, “intend”, “should”, and similar expressions. Forward–looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward–looking information. The Company’s actual results could differ materially from those anticipated in this forward–looking information as a result of competitive factors and competition for investment opportunities, challenges relating to operations in international markets, transaction execution risk, changes to the Company’s strategic growth plans, and other factors, many of which are beyond the control of the Company. The Company believes that the expectations reflected in the forward–looking information are reasonable based on current expectations and potential investment pipeline, but no assurance can be given that these expectations will prove to be correct and such forward–looking information should not be unduly relied upon. Any forward–looking information contained in this news release represents the Company’s expectations as of the date hereof and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward–looking information whether as a result of new information, future events or otherwise, except as required by applicable securities legislation.

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/new-wave-subsidiary-n2-logics-enters-partnership-agreement-with-toronto-based-naturopathic-doctor-dr-elizabeth-goldspink-to-collaborate-on-multiple-developments-301245479.html

SOURCE New Wave Holdings Corp.

Cision
Cision

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/March2021/11/c6916.html

Posted on

BETTER PLANT APPOINTS BRANDING EXPERT PERRY CHUA AS CHIEF CREATIVE OFFICER

Vancouver, B.C. – March 9, 2021: Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant” or the “Company”) is pleased to announce the appointment of Perry Chua as Chief Creative Officer of the Company. Mr. Chua previously held the position of Creative Director since 2019, and will assume duties as Chief Creative Officer immediately. In this role, Mr. Chua will be responsible for leading the creative team as Better Plant continues to expand.

“Perry is a highly driven creative leader, with a proven ability to deliver innovative and lasting brand designs in a short period of time,” said Penny White, CEO of Better Plant. “We look forward to seeing Perry use his exceptional creative ability and outside-of-the-box thinking to lead his team in the development and evolution of Better Plant’s brands.”

Mr. Chua is an internationally sought-after brand designer with over two decades of experience working with clients including Nokia, McDonald’s Restaurants, Mountain Equipment Co-op, Four Seasons Private Residences, Urban Barn and NGRAIN. Mr. Chua has consistently pushed to create clean, compelling, unforgettable designs. Mr. Chua has earned several awards from international entities including The One Show, Applied Arts, Lotus Awards, HOW International Design Awards, ADCC and Communication Arts, among others.

In addition to being interviewed by Inc. Magazine for his brand expertise, Mr. Chua’s work has been featured on CBS News’ Design Innovation and can also be found in international journals from Canada, the U.S., Spain, China and the UK. Mr. Chua is also the co-author of Logo Savvy: Top Brand-design Firms Share their Naming and Identity Strategies, and author of The Best of Brochure Design 10.

“I’m honoured to be appointed as Chief Creative Officer of Better Plant Sciences and to be given the opportunity to lead our extraordinary creative team, which is made up of some of the most talented people in the business,” said Chua. “This exciting, nascent industry has the ability to change lives and I look forward to working with the team to push the limits and question norms to deliver truly memorable brand experiences.”

 

About Better Plant

Better Plant offers plant-based products for optimum health and wellness. It is a vertically integrated company with a team whose complementary experience enables acquisition, development, manufacturing, and direct-to-consumer distribution of its products. Its all-natural products vary from juice cleanses to home products to personal care products, all without chemicals or harmful ingredients. It has an extensive catalogue of over 400 proprietary plant-based product formulas. Better Plant currently has over 70 plant-based products for sale through eCommerce and/or in retail stores under the brands Jusu, Urban Juve, and Wright & Well. Better Plant also offers operational and support services to companies in which it has an equity interest. Better Plant also owns approximately 27.7% of NeonMind Biosciences Inc. (CSE:NEON) | (OTC:NMDBF).

For more information on Better Plant, visit betterplantsciences.com or follow @betterplantsciences on Instagram.

Penny White, President & CEO
penny@betterplantsciences.com
1-833-515-2677

Investor Relations:

Alexandra Dumanski
invest@betterplantsciences.com
1-833-515-2677

 

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation. Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of COVID-19, the potential for not acquiring any rights as a result of the patent application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen. Demand for the company’s products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets. Better Plant cautions readers not to place undue reliance on forward-looking statements provided by Better Plant, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better Plant expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

Posted on

BETTER PLANT APPOINTS GABRIEL VILLABLANCA AS VICE PRESIDENT OF MARKETING

Vancouver, B.C. – March 02, 2021: Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant” or the “Company”) is pleased to announce the appointment of Gabriel Villablanca as its Vice President of Marketing. Villablanca previously held the position of Director of eCommerce and will assume duties as VP of Marketing immediately. In this role, he will be responsible for leading marketing strategy as Better Plant’s brands continue to expand.

“Gabriel’s extensive experience in eCommerce and digital marketing across an array of brands is a huge asset to Better Plant,” said Penny White, CEO of Better Plant. “We have plans to expand our offering of plant-based products while building a more entertaining, customized and rewarding digital experience for our customers. eCommerce is a key aspect of our sales strategy and Gabriel will play a crucial role in elevating our marketing programs across all platforms.”

Villablanca brings more than 13 years of expertise in directing digital marketing efforts for B2B and B2C brands across North America, Europe and Australia with a proven track record of driving business results through innovative campaigns and building high-performance teams. Most recently, he held the role of Digital Marketing Director for O2E Brands for over six years. During his time there, he led digital marketing efforts for a range of well-recognized consumer brands including 1-800-JUNK?, You Move Me, WOW 1 DAY PAINTING and Shack Shine.

“I am incredibly excited to take on this new role with the Better Plant team as Vice President of Marketing,” said Villablanca. “In the coming months I will focus on fine tuning our marketing processes in several major areas: refining our customer journey, core values, acquisition strategies, and how we can further use data to make better marketing decisions.”

 

About Better Plant Sciences Inc.

Better Plant offers plant-based products for optimum health and wellness. It is a vertically integrated company with a team whose complementary experience enables acquisition, development, manufacturing, and direct-to-consumer distribution of its products. Its all-natural products vary from juice cleanses to home products to personal care products, all without chemicals or harmful ingredients. It has an extensive catalogue of over 400 proprietary plant-based product formulas. Better Plant currently has over 70 plant-based products for sale through eCommerce and/or in retail stores under the brands Jusu, Urban Juve, and Wright & Well. Better Plant also offers operational and support services to companies in which it has an equity interest. Better Plant also owns approximately 27.7% of NeonMind Biosciences Inc. (CSE:NEON).

 

For more information on Better Plant, visit betterplantsciences.com or follow @betterplantsciences on Instagram.

 

Penny White, President & CEO

penny@betterplantsciences.com

1-833-515-2677

 

Investor Relations:

Alexandra Dumanski

invest@betterplantsciences.com

1-833-515-2677

 

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

 

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation.  Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements.  Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of COVID-19, the potential for not acquiring any rights as a result of the patent  application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen.  Demand for the company’s products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets.  Better Plant cautions readers not to place undue reliance on forward-looking statements provided by Better Plant, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better Plant expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

Posted on

Psychedelic Special Task Force – Report on Psychedelics

Numinus and MAPS reach trial milestone

In a first-of-its-kind trial in Canada, Numinus Wellness (CSE: NUMI) has partnered with MAPS Public Benefit Corporation to collaborate for research on MDMA-assisted therapy. The “single-arm, open-label, compassionate access 1” trial has met several key milestones to enter a pre-implementation stage.

Aiming to expand access and treatment options to patients with PTSD, these significant developments will help gain better understanding of psychedelic-assisted psychotherapies as viable, safe, and necessary.

Who’s who?

  • Eight Numinus therapists working on this trial graduated in November 2020 from Part B of the MAPS-standardized MDMA therapist training program.
  • Dr. Devon Christie, Medical & Therapeutic Services Director at Numinus, was trained in this program and will serve as both the trial’s Principal Investigator and as a therapist.
  • MAPS Public Benefit Corporation, a subsidiary of MAPS, was formed to develop healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics.

Neither the FDA or Health Canada have approved this therapy just yet. The safety and efficacy of MDMA-assisted psychotherapy are still under investigation.

NYU Langone and MindMed launch psychedelic center

Operating with an endorsement by NYU Langone’s Department of Psychiatry, the one-of-a-kind health center continues to advance progress in psychedelic medicine through their Psychedelic Medicine Research Training Program.

The program will support development of early-career faculty members and post-doctoral fellows to become independent investigators in the field of psychedelic medicine. Treatment models & training programs developed at the center will scale psychedelic medicines into mainstream adoption by psychiatrists & therapists in America.

They have a lot going on.

Research at the center has and still focuses on the treatment of advanced cancer-related psychiatric and existential distress, addiction, major depression and PTSD.

  • Phase II clinical trial nearing completion to examine the use of psilocybin in treating alcohol use disorder, and developing a Phase II/III trial.
  • Phase II study from 2016 is now in Phase III development, with a funding proposal under review with the National Cancer Institute.
  • Recruitment underway for Phase II study to evaluate the efficacy of psilocybin in the context of “set and setting” therapy for individuals with major depressive disorder.
  • Recently completed a Phase III study on the safety and efficacy of psychotherapy utilizing MDMA for treatment of severe PTSD, and began recruitment for a second Phase III study.
  • Other studies are examining the use of psychedelics for disorders including chronic pain, end-of-life psychotherapy, opioid & tobacco addiction, and more.

Philanthropic efforts have kept the momentum going.

Major philanthropic support from donors have enabled medical breakthroughs and totaled over $10 million in support for studies at NYU Langone.

  • MindMed (OTCM: MMEDF) leads the way with $5 million contribution.
  • Scientist & philanthropist Carey Turnbull: $1 million
  • Private investor Alan Fournier: $2 million
  • President of the Usona Institute, Bill Linton: $1 million
  • Other significant donors include the George Sarlo Foundation, Cody Swift of the Riverstyx Foundation and Dr. Bronner’s Soaps.

Massachusetts is looking to decriminalize all drugs

It’s clear that current drug enforcement regulations are creating an unjust number of arrests and prosecutions in fragile communities. That’s why lawmakers introduced legislation in Massachusetts aiming to end the state’s war on drugs, which has disproportionately targeted racial minorities.

The statewide bill HD.3439 was introduced on Friday to challenge current criminal penalties for the possession of controlled substances in Section 34. These efforts come alongside bills SD.2248 and HD.3829 that aim to solve racial injustice and evaluate the impact of these new regulations.

What are they trying to pass?

  • Remove criminal penalties for possession of all drugs.
  • Legalize and regulate psychedelic substances, including possession, consumption, transportation, and sale of entheogenic plants and fungi.
  • Establish a 21-person task force to conduct studies on entheogenics.
  • Civil fine of up to $50, or submitting to screening for health and economic evaluation in order to provide services to the individual rather than an economic punishment.
  • Completion of this screening won’t be deemed as an admission of criminal charges.
  • Failure to pay the fine won’t incur penalties or incarceration.

What’s up with this “task force”?

  • They will develop recommendations:
    • On how to legalize psychedelic substances “in a manner that maximizes equitable access and sustainable manufacture of these plants.”
    • Regarding “pardons, parole, diversion, expungement, and equity measures” for people with prior criminal records due to possession, or distribution of these substances.

These recommendations will be used to draft legislation to be put into effect no later than June 2022.

UC San Diego researchers are exploring psychedelics to treat phantom limb pain

Imagine losing a limb yet still experiencing chronic pain out of thin air. The phenomena, known as ‘phantom limb’ is a commonly debilitating sensation that a limb is still physically there, because the brain interprets it as such.

The result is lingering pain with no effective solution for up to 80% of the world’s 40 million amputees (according to WHO).

Study Details

Timothy Furnish, MD, clinical professor of anesthesiology at UC San Diego School of Medicine had this to say:

  • The clinical trial will enroll 30 amputees suffering from phantom pain to receive 25 milligrams of psilocybin; another 30 will receive a placebo (niacin).

The trial will assess pain and psychological functioning, including magnetic resonance imaging.

Awakn announces AUD study results

The world’s first MDMA clinical trial addressing alcohol use disorder (AUD) has now provided definitive, promising results. The outcome of the study conducted by Awakn Life Sciences: all patients tolerated the treatment well, and with no adverse reactions. Further trials will now ensue.

  • Dr. Ben Sessa, Chief Medical Officer at Awakn, conducted the Bristol Imperial MDMA in Alcoholism (BIMA) trial.
  • The study evaluated patients’ drinking behavior, quality of life and psycho-social functioning.
  • Phase IIb study in the UK will now proceed. It will be a double-blind, placebo-controlled clinical trial to further investigate safety and efficacy of MDMA.

This is a really big deal.

  • The first clinical research study using MDMA-assisted psychotherapy to treat any addiction, and it was totally successful! Improvements by all measures were clinically observed.
  • Currently available treatments are greatly ineffective, with a high rate of relapse.
  • Alcohol abuse is the most prevalent substance disorder in the world, and one of the top 5 causes of disease and disability in Europe.
  • In the UK, alcohol is the leading cause of diseases for over 20% of the adult population.
  • It’s expected that the COVID-19 pandemic will make matters worse.

Report Readout

Frontier Acquisition Corp, a special purpose acquisition company (SPAC) sponsored by German investor Christian Angermayer, a major backer of COMPASS, will launch biotech SPAC in the U.S.

Mindset landed an international contract to develop and manufacture synthetic psilocybin.

Mind Cure adds global technology leader Robert C. Hill to Board of Directors.

Edmonton psychiatry professor founding new company by studying psychedelic effects on mental health.

Columbia professor turns heads with bold statements on his recreational use of drugs.

Psychedelic drug therapy now offered at Calgary clinic to treat depression, anxiety, PTSD.

Universal Ibogaine Inc. announces appointment of Dr. Rami Batal as Chief Executive Officer.

PharmaTher to collaborate with Terasaki Institute for Novel Microneedle Delivery of Psychedelic Pharmaceuticals.

Therapists could be influencing mystic, spiritual experiences and meaning while patients are on psychedelics.

Entheon Biomedical and Science in Action received ethics approval for in vivo non-GLP toxicology study of DMT.

Hawaii bill dies in session, opposed by the state Department of Health as well as county police departments.

Field Trip Health secures $50 million offering of common shares with Bloom Burton Securities Inc.

DEA gives green light for Psilera’s mission to study new DMT and psilocybin treatments for central nervous system disorders.

Optimi Health Corp goes public, completing a $20.7 million IPO.

Posted on

BETTER PLANT’S URBAN JUVE EXPANDS DISTRIBUTION INTO NEW CANADIAN RETAIL LOCATIONS

Vancouver, B.C. –  February 11, 2021: Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”or the “Company”) is pleased to announce that on January 4, 2021 it added Nature’s Fare Markets (“Nature’s Fare”) to its list of trusted retailers. Nature’s Fare is a retail chain that operates in British Columbia, Canada, and is most popular amongst wellness conscious consumers for trusted, natural products.

Nature’s Fare is Canada’s first certified B Corporation. Certified B Corporations are businesses that meet the highest standards of verified social and environmental performance, public transparency, and legal accountability to balance profit and purpose. They are committed to responsible and sustainable products, making it an excellent fit for Urban Juve. Nature’s Fare has seven locations across BC.

“We are excited about bringing on Urban Juve products,” says Lisa Ramsay, Vitamin Manager at Nature’s Fare in White Rock, BC. “The natural plant-based hyaluronic acid in their Skin Awakening Serum is something our customers have been seeking out, and not something we have seen before.”

Ecotrend Ecologics (“Ecotrend”) is Urban Juve’s Canadian distributor and has proven itself to be an excellent fit with the brand. Ecotrend is also a certified B Corporation, in addition to being Climate Smart certified. Climate Smart is a government-approved program that requires a detailed assessment of all aspects of a company’s climate footprint. It is the only company in the Health and Wellness industry in Canada that has committed itself to this level of environmental stewardship. Ecotrend manages over 2500 natural health retailers and over 2500 professional accounts.

Urban Juve is currently available in select locations in over 50 retail stores across Canada, including Pharmasave , Nesters Market, online wellness giant Vitasave.ca, and La Moisson’s flagship store.

La Moisson, a high integrity natural health store in Quebec City, now carries the entire line of Urban Juve products. This demonstrates La Moisson’s belief in the product’s quality and shelf appeal.

“Urban Juve packaging is fully compliant in Quebec, which makes us well-positioned to take on the French-Canadian natural health and beauty product market with the help of our Ecotrend reps in this region,” says Amber Allen, Head of Sales for Better Plant.

The Company is also committed to building a strong educational foundation and identifies as a wellness education brand. It accomplishes this through providing distributors and retailers with ongoing high-level product training and wellness education.

Urban Juve products are available at www.urbanjuve.com. For Canadian purchasing inquiries contact: marketing.manager@ecotrend.ca.

About Better Plant Sciences Inc. 

Better Plant offers plant-based products for optimum health and wellness. It is a vertically integrated company with a team whose complementary experience enables acquisition, development, manufacturing, and direct-to-consumer distribution of its products. Its all-natural products vary in use from pain treatment to disease prevention to skin care, all without chemicals or harmful ingredients. It has an extensive catalogue of over 400 proprietary product formulas. Better Plant currently has over 70 plant-based products for sale through eCommerce and/or in retail stores under the brands Jusu, Urban Juve, and Wright & Well. Better Plant also owns approximately 28.6% of NeonMind.

For more information on Better Plant, visit betterplantsciences.com or follow @betterplantsciences  on Instagram.

Penny White, President & CEO

penny@betterplantsciences.com

1-833-515-2677

Investor Relations:

Alexandra Dumanski

invest@betterplantsciences.com 

1-833-515-2677

 

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation.  Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements.  Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of COVID-19, the potential for not acquiring any rights as a result of the patent  application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen.  Demand for the company’s products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets.  Better cautions readers not to place undue reliance on forward-looking statements provided by Better, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

Posted on

BETTER PLANT’S JUSU BEGINS EXPANSION INTO U.S. MARKET

Vancouver, B.C. – February 4, 2021: Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) is pleased to announce it has engaged the Thank You Merci’s sales and merchandising team (“TYM”) to represent Jusu Body, Jusu Life, and Jusu Juice; commencing immediately. TYM offers full-service sales representation and key account management for all channels in Canada & the USA.  Better Plant already sells its wholly owned Jusu brands through its direct-to-consumer eCommerce platforms and is now augmenting those sales through retail channels.

Jusu Body consists of approximately 40 body and face products crafted from 100% plant-based ingredients.  Jusu Life products include five home cleaning products with no chemicals that are also 100% plant-based. All products are available for purchase at getjusu.com. Jusu also has a proprietary line of all-natural pressed juices that are sold at the Jusu juice bar location at Cadboro Bay, Victoria and sold through direct-to-consumer platforms in Victoria, British Columbia and Calgary, Alberta.

TYM manages key accounts in the natural health and consumer packaged goods industry.  The TYM team is composed of 10 experienced sales and account managers with over 16 years’ experience in the natural health industry.

“We are excited to be part of the launch and expansion of JUSU into the U.S. market. We feel we can help the brand explore direct and distributor partnerships with retailers from independent stores to national chains,” says TYM Founder and CEO, Lindsay Blakeman “Jusu products deliver high quality, innovative and on-trend products that we couldn’t be more thrilled to represent.”

Prior to founding Thank You Merci, Lindsay Blakeman worked with well-established brands such as Vega, Caulipower and Ancient Nutrition in both Canada and the U.S.

“Adding Thank You Merci’s esteemed sales and merchandising teams to represent Jusu products is a strategic move based on their extensive experience in the all-natural health and consumer packaged goods industry” says Better Plant’s Head of Sales, Amber Allen. “The timing could not have been better with our entry into the U.S. market, to fully capitalize on their established relationships across North America.”

According to a report by Prophecy Market Insights, the global vegan beauty products market accounted for US$ 14.3 billion in 2019 and is estimated to be US$ 25.3 billion by 2029 and is anticipated to register a CAGR of 5.9%.

Jusu Life, Body and Home products are available in Canada at www.getjusu.com. For U.S. purchasing inquiries visit: www.thankyoumercisales.com.

 

About Better Plant Sciences Inc.

Better Plant offers plant-based products for optimum health and wellness. It is a vertically integrated company with a team whose complementary experience enables acquisition, development, manufacturing, and direct-to-consumer distribution of its products. Its all-natural products vary in use from pain treatment to disease prevention to skin care, all without chemicals or harmful ingredients. It has an extensive catalogue of over 400 proprietary product formulas. Better Plant currently has over 70 plant-based products for sale through eCommerce and/or in retail stores under the brands Jusu, Urban Juve, and Wright & Well. Better Plant also owns approximately 28.7% of NeonMind.

For more information on Better Plant, visit betterplantsciences.com or follow @betterplantsciences on Instagram.

Penny White, President & CEO

penny@betterplantsciences.com

1-833-515-2677

 

Investor Relations:

Alexandra Dumanski

invest@betterplantsciences.com

1-833-515-2677

 

Sales Inquiries:

Amber Allen

amber@betterplantsciences.com

604-808-8118

 

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation.  Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements.  Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of COVID-19, the potential for not acquiring any rights as a result of the patent  application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen.  Demand for the company’s products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets.  Better cautions readers not to place undue reliance on forward-looking statements provided by Better, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

Posted on

BETTER PLANT APPOINTS PURE PRODUCT BROKERS FOR SALES IN U.S., AUSTRALIA AND JAPAN

Vancouver, B.C. – January 26, 2021: Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) is pleased to announce it has engaged Pure Product Brokers for sales representation for Better Plant’s Urban Juve products, commencing immediately.

Urban Juve is a plant-based skincare line based on Ayurveda and holistic healing principles. Urban Juve has a complete line of face serum, face moisturizers, face mists, body oils, and a lip balm that are crafted plant-based ingredients.

Pure Product Brokers Founder and President, Maureen Malloy, is trained as a Registered Nurse in the state of California and has 25 years of experience in the Beauty and Wellness industry growing multiple brands into retail successes at a national level. “I always look at a brand in terms of balance of innovation and familiarity, whether it’s in formulation, packaging or marketing style,” says Ms. Malloy. “Urban Juve is right on time with this super-intelligent skincare system. No one has done Ayurvedic formulation to this level of quality before.”

Pure Product Brokers represent a wide range of carefully chosen brand partners in the natural skincare space and has successfully launched brands at a national level with such retailers as Sephora and Nordstrom.

“In addition to sharing our company values, Maureen and her team have a proven track record of success and are well-respected for their work in the beauty industry,” says Amber Allen, Director of Sales for Better Plant. “I look forward to uniting our efforts to bring Urban Juve to new markets and diversifying our distribution channels to reach more customers.”

As sales representatives, Pure Product Brokers will solicit orders for Urban Juve products in the US, Australia, Japan, and any additional regions mutually agreed to by both parties. Under the agreement Pure Products will engage in the sales and promotion of products to develop initiate and increase volume of business for Urban Juve, provide continual education to regional and headquarter buyers and retail sales teams, coordinate launch and seasonal education events and educational support for retail sales teams, and consult Urban Juve on best practices required to create a successful product launch within the targeted channels of business and within specific key account formats.

 

About Better Plant Sciences Inc.

Better Plant offers plant-based products for optimum health and wellness. It is a vertically integrated company with a team whose complementary experience enables acquisition, development, manufacturing, and direct-to-consumer distribution of its products. Its all-natural products vary in use from pain treatment to disease prevention to skin care, all without chemicals or harmful ingredients. It has an extensive catalogue of over 400 proprietary product formulas. Better Plant currently has over 70 plant-based products for sale through eCommerce and/or in retail stores under the brands Jusu, Urban Juve, and Wright & Well. Better Plant also owns approximately 29% of NeonMind Biosciences Inc.

For more information on Better Plant, visit betterplantsciences.com or follow @betterplantsciences on Instagram.  Buy Urban Juve products at urbanjuve.com or follow @urbanjuve on Instagram.

 

Penny White, President & CEO

penny@betterplantsciences.com

1-833-515-2677

 

Investor Relations:

Alexandra Dumanski

invest@betterplantsciences.com

1-833-515-2677

 

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

 

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation.  Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements.  Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of COVID-19, the potential for not acquiring any rights as a result of the patent  application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen.  Demand for the company’s products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets.  Better Plant cautions readers not to place undue reliance on forward-looking statements provided by Better Plant, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better Plant expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

Posted on

/C O R R E C T I O N from Source — New Wave Holdings Corp./

In the news release, New Wave: Welcomes Iman Nevab, Homeopathic Research Expert to the Scientific Advisory Board, issued 21-Jan-2021 by New Wave Holdings Corp. over CNW, we are advised by the company that the headline should read “Iman Navab” rather than “Iman Nevab.” Also, in the About the Company section, the OTC ticker should be ”TRMNF” instead of ”TRMND” as originally issued inadvertently. The complete, corrected release follows:

New Wave: Welcomes Iman Navab, Homeopathic Research Expert to the Scientific Advisory Board

TORONTO, Jan. 21, 2021 /CNW/ – NEW WAVE HOLDINGS CORP. (the “Company” or “New Wave”) (CSE: SPOR) (FWB: 0XM2) (OTCPK: TRMNF) an investment issuer that provides capital and support services, announced its latest addition to the scientific advisory board.

New Wave Holdings Logo (CNW Group/New Wave Holdings Corp.)
New Wave Holdings Logo (CNW Group/New Wave Holdings Corp.)

New Wave Holdings Announces New Scientific Advisory Board Member

New Wave Holdings Corp. announced today the appointment of a new member to their scientific advisory board. Iman Navab will be joining Dennis McKenna and Dr. Richard Knowles on New Wave’s expert advisory board – providing innovative guidance and insight to support the company’s continued growth and development in the blooming psychedelic and functioning mushroom sector.

Mr. Navab is a registered healthcare provider and brings years of experience to the table as a homeopathic practitioner, researcher, botanist, and historian of homeopathy. He is the president of the Applied Research in Homeopathy Foundation of Canada and has authored two books – Miasma of Cancer and An Interview with Samuel Hahnemann.

With his extensive knowledge in homeopathy and six years of academic studies in natural medicine at a prominent Canadian college under his belt, Mr. Navab will utilize his skills and expertise to leverage New Wave Holdings’ strategic positioning in the industry.

“It is with great pleasure that we are formally introducing our newest member to the advisory team,” said Daniel Fox, CEO of New Wave Holdings Corp. “Mr. Navab has a wealth of experience in homeopathy and alternative medicine, and his expertise and insights will be invaluable to our company’s continuing endeavors in the psychedelic sector. We look forward to exponential growth and progress in the upcoming years with the help of our impressive panel of experts in the field.”

In addition to his expertise in natural medicine, he is also the founder of Dynamise, a company that focuses on the development and creation of natural skincare and health products that are backed by science and research.

“It is an honour to be a member of New Wave’s scientific advisory board. I strongly believe that science of mycology and herbology has great medicinal benefits for the wellbeing of mankind, which must be explored diligently. As Albert Einstein said – Look deep into nature, and then you will understand everything better.” Said Mr. Navab.

ABOUT NEW WAVE HOLDINGS CORP.

New Wave Holdings Corp. (CSE: SPOR, FWB: 0XM2, OTC: TRMNF) is an investment issuer focused on rapid growth in the Nutraceutical space, with an impressive and growing number of organic plant-based health care products. New Wave is also focusing on the burgeoning psychedelic sector and support for adaptive and progressive mental health products and therapies. In the psychedelic sector, New Wave will focus on supporting research on active psychedelic compounds, focused on the creation of consumer products New Wave also contains various health and beauty products within its portfolio of non-psychoactive plants and fungi as it continues to expand its product distribution through vertical integration to provide end to end solutions while capturing a high margin business model.

Investors interested in connecting with New Wave Holdings can learn more about the company and contact the team at http://newwavecorp.com.

The CSE has not in any way passed on the merits of the Acquisition, and neither has approved nor disapproved the contents of this press release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

FORWARD-LOOKING INFORMATION DISCLAIMER

Certain statements contained in this news release may constitute forward–looking information, including but not limited to, applicable regulatory approval in connection with the Acquisition, the closing of the Acquisition, expansion of operations, size and quality of future tournaments and projections regarding attendance at future events. Forward–looking information is often, but not always, identified by the use of words such as “anticipate”, “plan”, “estimate”, “expect”, “may”, “will”, “intend”, “should”, and similar expressions. Forward–looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward–looking information. The Company’s actual results could differ materially from those anticipated in this forward–looking information as a result of competitive factors and competition for investment opportunities, challenges relating to operations in international markets, transaction execution risk, changes to the Company’s strategic growth plans, and other factors, many of which are beyond the control of the Company. The Company believes that the expectations reflected in the forward–looking information are reasonable based on current expectations and potential investment pipeline, but no assurance can be given that these expectations will prove to be correct and such forward–looking information should not be unduly relied upon. Any forward–looking information contained in this news release represents the Company’s expectations as of the date hereof and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward–looking information whether as a result of new information, future events or otherwise, except as required by applicable securities legislation.

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/new-wave-welcomes-iman-navab-homeopathic-research-expert-to-the-scientific-advisory-board-301212701.html

SOURCE New Wave Holdings Corp.

Cision
Cision

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/January2021/21/c2310.html